Dr Reddys Laboratories (RDY) Non-Current Deferred Tax Liability (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Non-Current Deferred Tax Liability for 10 consecutive years, with $166.0 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability rose 0.61% year-over-year to $166.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $166.0 million (up 0.61% YoY) and the FY2026 annual result came in at $166.0 million, up 0.61% from the prior year.
• Non-Current Deferred Tax Liability advanced to $166.0 million in Q1 2026 per RDY's latest filing, from $165.0 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for RDY reached as high as $166.0 million in Q1 2026 and fell as low as $1.0 million in Q1 2022.
• A 5-year average of $70.6 million and a median of $11.0 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability sank 80.0% — and 2025, when it soared 1400.0%.
• Year by year, Non-Current Deferred Tax Liability stood at $1.0 million in 2022, then surged by 900.0% to $10.0 million in 2023, then rose by 10.0% to $11.0 million in 2024, then surged by 1400.0% to $165.0 million in 2025, then increased by 0.61% to $166.0 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $166.0 million, $165.0 million, and $11.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.